NovaBay Pharmaceuticals, Inc. - NBY STOCK NEWS

NovaBay Pharmaceuticals reported a 46% increase in total sales for Q1 2022, totaling $2.6 million, driven by the acquisition of DERMAdoctor. Avenova Spray unit sales rose 15%, despite a decline in revenue from $1.6 million to $1.4 million due to unexpected returns. Gross margins fell to 58% from 75% in the prior year, attributed to these returns. Operating expenses increased to $3.9 million including costs related to DERMAdoctor. Net loss decreased to $111,000 from $1.5 million year-over-year.

NovaBay Pharmaceuticals (NBY) has announced the launch of next-generation skincare products as part of its popular product lines, Kakadu C and Calm Cool + Corrected. These new formulas incorporate anti-aging ingredients to target wrinkles, fine lines, and skin discoloration, specifically catering to both normal and sensitive skin types. The Kakadu C serum combines retinol with vitamin C, while the Bakuchiol-based Calm Cool + Corrected serum offers a gentle alternative suitable for sensitive skin. Both products aim to deliver visible results and enhance skin vitality.

NovaBay Pharmaceuticals (NBY) will announce its financial results for Q1 2022 on May 12, 2022, after market close, followed by a conference call at 4:30 p.m. ET. Participants can pre-register for immediate access or dial in live. A replay of the call will be available from two hours after its conclusion until June 2, 2022. NovaBay focuses on developing and selling products in the eyecare and skincare markets, notably its Avenova antimicrobial spray. The company recently acquired DERMAdoctor, enhancing its skincare portfolio.

NovaBay Pharmaceuticals (NBY) reports significant advancements following its acquisition of DERMAdoctor, enhancing its market presence in the eyecare and skincare sectors. The Avenova product line saw a 15% sales increase, with 74% of revenue from non-prescription sales. New innovative products are being introduced under Avenova and DERMAdoctor, leveraging a low-cost model for market testing. The company aims to tap into the growing global lash extension market, projected to reach $2.4 billion by 2031. Despite minor supply chain disruptions, NovaBay anticipates major growth in the latter half of 2022.

NovaBay Pharmaceuticals (NYSE: NBY) will showcase Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on QVC's 'Get Ready, Gorgeous with Ali' on April 12 at 8 a.m. Eastern Time. This product aims to relieve minor irritations and itching for the estimated 31 million Americans suffering from eczema. It features National Eczema Association Seal of Acceptance for meeting rigorous standards. The balm was previously introduced successfully to QVC viewers, highlighting its market potential.

NovaBay Pharmaceuticals has launched a new product, Hydrating Cleansing Oil, under the DERMAdoctor Calm Cool + Corrected brand. This soap-free, pH-balanced formula is designed to moisturize and remove makeup without drying the skin, specifically targeting dry, sensitive, or eczema-prone skin. Priced at $30.00 for 200 ml, it features ingredients like jojoba seed and orange peel oils. The product is available on platforms like Amazon.com and dermadoctor.com.

NovaBay Pharmaceuticals, Inc. (NBY) reported a 40% increase in fourth quarter net product revenue, totaling $2.6 million, primarily driven by strong sales of the Avenova spray. Avenova's sales were up 15% for the year, with unit sales growing 31%. The company also completed the acquisition of DERMAdoctor, diversifying its product line. While operating expenses rose to $4.6 million, net loss decreased to $0.9 million from $1.8 million year-over-year. Revenue for 2021 was $8.4 million, down from $9.9 million in 2020, due to a lack of PPE product sales.

NovaBay Pharmaceuticals (NYSE American: NBY) will report its financial results for the fiscal year ending December 31, 2021, on March 29, 2022, after market close. An investment community conference call will follow at 4:30 p.m. ET. Participants can pre-register for the call, which will also be available via live webcast. NovaBay, known for Avenova, the leading antimicrobial lid and lash spray, acquired DERMAdoctor in November 2021, enhancing its product offerings in skincare.

NovaBay Pharmaceuticals (NYSE American: NBY) announces the launch of its new Moisture Recovery HA Serum, designed specifically for dry, eczema-prone skin. This innovative serum features hyaluronic acid, Vitamin C, and unique botanical ingredients, promising hydration and skin repair. Priced at $48.00 for a 30 ml bottle, the serum is available on Amazon and dermadoctor.com. Dermatologist Dr. Audrey Kunin emphasized its benefits for sensitive skin.